Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Prostate Cancer: early-phase trial registry
275 of 749 indexed Prostate Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4 of 28,707 conditions by registered trial count.
749 US clinical trials · 275 currently recruiting · #4 of 28,707 conditions by registered trial count
Prostate Cancer: 749 US clinical trials tracked, 275 recruiting.
Prostate Cancer is the subject of 749 registered US clinical trials on ClinicalTrials.gov, 275 of them currently open to new participants. 75 are in Phase 3-4 (later-stage) and 344 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 53 of these trials.
Enrollment posture brief
Registry condition prostate-cancer
OPEN 275 | RECR 37% | LATE 75 | EARLY 344 | RANK #4 | SPON 53
Volume-matched condition peers
Nearest open-share peer: Chronic Disease (37% recruiting · 49 trials)
Prostate Cancer lists 275 open slots (37% of 749 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Prostate Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Prostate Cancer recruits in line with its size-band peers.
275 of 749 indexed trials (36.7%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Prostate Cancer trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 53 of 749 trials (7.1%). 283 distinct sponsors appear on at least one study for this condition label.
-
Typical Prostate Cancer enrolment sits around 82 participants.
Median target enrolment is 82 among the 736 trials that report a genuine target (sentinel values excluded). 389 of those (52.9%) plan for fewer than 100 participants.
-
Prostate Cancer research is mostly interventional.
628 interventional and 121 observational studies make up this index (83.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
749 total, page 11 of 15
PACCT: Partnering Around Cancer Clinical Trials
Susan Eggly
NCT02906241
CyberKnife Radiosurgery For Low & Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry
Accuray Incorporated
NCT00643617
Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer
M.D. Anderson Cancer Center
NCT00002855
OPTimizing Treatment Focused Genetic Testing IN Cancer
Dana-Farber Cancer Institute
NCT04066361
Redes III Patient Navigator Qol Study
The University of Texas Health Science Center at San Antonio
NCT02275754
C11-Sodium Acetate PET/CT Imaging for Metastatic Disease in Intermediate-to-high Risk Prostate Adenocarcinoma
Phoenix Molecular Imaging
NCT01530269
Study of Sildenafil Citrate During and After Radiotherapy/Hormone Therapy for Erectile Function Versus Radiotherapy/Hormone Therapy for Prostate Cancer
Memorial Sloan Kettering Cancer Center
NCT00142506
Prospective Clinical Utility Study to Assess the Impact of Decipher on Treatment Decisions After Surgery
GenomeDx Biosciences
NCT02080689
Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer
Eastern Cooperative Oncology Group
NCT00060398
Open Registry Measuring Impact of Genomic Testing on Treatment Decision After Biopsy in Newly Diagnosed Prostate Cancer Patients
Myriad Genetic Laboratories
NCT02209584
Prostate Cancer: Family Care for Patients and Spouses
University of Michigan
NCT00708968
PSMA and C-11 Choline PET in Patients With Biochemical Recurrence of Prostate Cancer
Mayo Clinic
NCT03768349
A Randomized Study of the Efficacy of Low Venous Pressure General Anesthesia Versus Combined Spinal-Epidural Anesthesia in Decreasing Blood Loss During Prostate Surgery
Memorial Sloan Kettering Cancer Center
NCT00200187
Local Anesthesia for Prostate Biopsy
Mayo Clinic
NCT00422708
Tadalafil in Preventing Erectile Dysfunction in Patients With Prostate Cancer Treated With Radiation Therapy
Radiation Therapy Oncology Group
NCT00931528
Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer
Radiation Therapy Oncology Group
NCT01546987
Proton Therapy for Low and Intermediate Risk Prostate Cancer
University of Florida
NCT00693238
Prostate Cancer Survey
University of Maryland, Baltimore
NCT03128710
Technology Based Psychosocial Intervention for Symptom Management and HRQOL in Men Living With Advanced Prostate Cancer
Northwestern University
NCT03149185
The Impact of Low Pressure Pneumo in RARP
Metro Health, Michigan
NCT03370016
Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
Alliance for Clinical Trials in Oncology
NCT00377156
Best Systemic Therapy or Best Systemic Therapy (BST) Plus Definitive Treatment (Radiation or Surgery)
M.D. Anderson Cancer Center
NCT01751438
PROvenge Treatment and Early Cancer Treatment
Dendreon
NCT00779402
Study of Hypofractionated Proton Beam Radiation Therapy for Prostate Cancer
Loma Linda University
NCT00831623
Trial of Community Health Worker-led Decision Coaching
NYU Langone Health
NCT03726320
Fostering Shared Decision-making About Prostate Cancer Screening Among Clinicians and African American Men
Xavier University of Louisiana.
NCT03869216
Reduction of Prostate Biopsy Morbidity
Maimonides Medical Center
NCT03913039
Diet and PSA Levels in Patients With Prostate Cancer
Memorial Sloan Kettering Cancer Center
NCT00003367
Analysis of Prostate Cancer Short-Term Cultures Using Molecular Cytogenetic Methods
National Human Genome Research Institute (NHGRI)
NCT00022919
Proton-Based Stereotactic Ablative Body Radiotherapy for Prostate Cancer
Mayo Clinic
NCT03159676
Effects of Two Doses of MPX Capsules on Rising Prostate-specific Antigen Levels in Men Following Initial Therapy for Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT01317199
Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer
Nymox Corporation
NCT01620515
Prospective Randomized Trial of Seminal Vesicle-Sparing Prostatectomy and Nerve-Sparing Radical Prostatectomy in Men With Clinically Localized Prostate Cancer
University of Michigan
NCT01825642
External-Beam Radiation Therapy Plus Implanted Radiation Therapy in Treating Patients With Prostate Cancer
Radiation Therapy Oncology Group
NCT00006365
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen
Janssen Biotech
NCT01314118
A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
Astellas Pharma
NCT00106392
FACBC PET/CT for Recurrent Prostate Cancer
David M. Schuster, MD
NCT00562315
Use of Multi-Parametric MRI With Prostate Biopsy for Cancer Diagnosis.
NYU Langone Health
NCT01964638
Understanding the Value of Community Vital Signs in Primary Care
Virginia Commonwealth University
NCT02512835
A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)
Progenics Pharmaceuticals
NCT01695044
Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
Watson Pharmaceuticals
NCT01161563
18F-DCFBC PET/CT in Prostate Cancer
National Cancer Institute (NCI)
NCT02190279
A Selective Androgen Receptor Modulator for Symptom Management in Prostate Cancer
Dana-Farber Cancer Institute
NCT02499497
Study of Carbon Dioxide Exchange Patterns During Robotic Prostatectomies
OhioHealth
NCT02114164
Real-World Study of Enzalutamide and Abiraterone Acetate (With Prednisone) Tolerability
Janssen Scientific Affairs
NCT02663193
A Pilot Study of Geriatric Specific Interventions for Quality of Life in Elderly Patients With Cancer
Memorial Sloan Kettering Cancer Center
NCT00984321
Developing an Imaging-Based Tool to Identify Areas for Prostate Cancer Biopsy
University of Chicago
NCT03585660
Open Label Study of Sipuleucel-T in Metastatic Prostate Cancer
Dendreon
NCT00901342
Exploring Men s Prostate Cancer Genetic Risk Perceptions
H. Lee Moffitt Cancer Center and Research Institute
NCT06764992
Immune Responses in Prostate, Lung, Melanoma and Breast Cancer Patients Following Stereotactic Body Radiotherapy (SBRT), Intensity Modulated Radiotherapy (IMRT) or Brachytherapy
Mayo Clinic
NCT01777802
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 156 |
| Phase 2 | 188 |
| Phase 3 | 62 |
| Phase 4 | 13 |
Top Sponsors
Named interventions
Most-linked intervention names on Prostate Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Prostate Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Prostate Cancer page
749 registered trials, 275 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 275 Prostate Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Prostate Cancer trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Prostate Cancer condition card totals 749 registered trials; most-linked intervention Enzalutamide; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.